Abstract 1504
Background
Weight loss prior to cancer treatment carry a negative impact on clinical outcomes. However, few studies have addressed whether weight assessment over time is plagued by high dropout rates and whether weight change carries a prognostic association in the same manner as it does at baseline.
Methods
A pooled analysis of individual patient data was undertaken among non-small cell lung cancer patients who participated in prospective cancer treatment trials from the Alliance for Clinical Trials in Oncology from 1998-2008. This study examined 1) rates of missing weight data over time and 2) the prognostic association of weight beyond baseline assessment.
Results
822 chemotherapy-treated patients were examined. 659 (80%) were still on treatment at the beginning of cycle 2. Weight was available for 656 (80%) patients. However, by cycles 3 and 4, weight was available for only 448 (55%) and 384 (47%) patients, respectively. From baseline to immediately prior to cycle 2, 224 patients (34% of 656) lost more than 2% baseline weight, and 226 (34%) lost between 0 and 2%. With respect to prognostic associations, the median survival time from the beginning of cycle 2 was 6.9, 10.9, and 13.0 months for patients with weight loss of 2% or more, loss of < 2%, and those with weight gain, respectively. In multivariate analyses, after adjustment for age, gender, performance score, type of treatment, and body mass index, weight loss of 2% or more was associated with poor survival compared to weight loss of < 2% (hazard ratio (HR) = 1.57; 95% CI [1.27 to 1.95]; P <.001). Although weight gain was not associated with improved overall survival, it was associated with better progression-free survival outcomes (HR = 0.81; 95% CI [0.66 to 0.99]; P=.04).
Conclusions
Weight is a clinically useful endpoint and should be integrated into cancer cachexia trials because of its ease of frequent measurement and sustained prognostic association.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Fred C and Katherine B Andersen Foundation and the United States National Cancer Institute.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4925 - Prognostic role of CD73 in metastatic Non Small Cell Lung Cancer according to the presence of driver alterations
Presenter: Giulia Galli
Session: Poster Display session 1
Resources:
Abstract
785 - JAK-STAT inhibitor overcomes interferon γ-reduced, NK cell-mediated cytotoxicity in non-small-cell lung cancer cells
Presenter: Riki Okita
Session: Poster Display session 1
Resources:
Abstract
2326 - Low LATS2 expression is associated with poor prognosis in non small cell lung cancer
Presenter: Si-hyong Jang
Session: Poster Display session 1
Resources:
Abstract
5960 - Application of ESCAT and OncoKB scales in Liquid biopsy (LB) in Advanced NSCLC patients (pts): Is it feasible and reliable?
Presenter: Michael McCusker
Session: Poster Display session 1
Resources:
Abstract
4855 - IDH1R132H mutation induces a less aggressive phenotype of glioma cells and affects the radiosensitivity by interacting with Wnt/β-catenin signaling
Presenter: Xuetao Han
Session: Poster Display session 1
Resources:
Abstract
2641 - Impact of Angiopoietin-2 on glioblastoma response to combined chemo-radiotherapy
Presenter: Charly Helaine
Session: Poster Display session 1
Resources:
Abstract
5743 - The Discovery of RNA-aptamers That Selectively Bind and Inhibit Glioblastoma Stem Cells by targeting EphA2
Presenter: Alessandra Affinito
Session: Poster Display session 1
Resources:
Abstract
4160 - Impact of tumor reoxygenation by nanoparticles on Tumor Associated Macrophages (TAMs)
Presenter: Aurélie Ferré
Session: Poster Display session 1
Resources:
Abstract
2474 - Prognostic significance of c-Rel/p50 heterodimer in the tumor microenvironment of uveal melanoma
Presenter: Seema Kashyap
Session: Poster Display session 1
Resources:
Abstract
1769 - Synergistic role of BAP1 and DNA damage response pathway in uveal melanoma and its prognostic significance.
Presenter: JAYANTI JHA
Session: Poster Display session 1
Resources:
Abstract